MODERNA INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | MRNA |
| ISIN: |
MODERNA INC. news, videos and press releases
For more news please use our advanced search feature.
MODERNA INC. - More news...
MODERNA INC. - More news...
- 04/10/2025 - 07:00 Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
- 04/07/2025 - 07:00 Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
- 03/31/2025 - 07:00 Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
- 02/28/2025 - 10:30 Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
- 02/25/2025 - 07:00 Moderna to Present at Upcoming Conferences in March 2025
- 02/14/2025 - 06:28 Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
- 01/29/2025 - 07:00 Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
- 01/24/2025 - 06:30 Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
- 01/17/2025 - 16:28 Moderna Announces Updates on Pandemic Influenza Program
- 01/13/2025 - 07:00 Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
- 11/25/2024 - 07:00 Moderna to Present at Upcoming Conferences in December 2024
- 11/12/2024 - 08:15 Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
- 11/08/2024 - 07:30 Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
- 11/07/2024 - 06:30 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
- 10/31/2024 - 07:00 Moderna to Present at Upcoming Conferences in November 2024
- 10/24/2024 - 14:25 Moderna Named a Top Employer by Science for Tenth Consecutive Year
- 10/17/2024 - 07:05 Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
- 10/02/2024 - 07:00 Abbas Hussain Joins Moderna's Board of Directors
- 09/30/2024 - 20:00 Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
- 09/30/2024 - 07:00 Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
- 09/17/2024 - 11:00 Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
- 09/12/2024 - 06:00 Moderna R&D Day Highlights Progress and Strategic Priorities
- 09/09/2024 - 07:00 Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
- 09/05/2024 - 08:00 EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
- 09/03/2024 - 08:30 Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
- 09/02/2024 - 07:00 Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
- 08/23/2024 - 07:00 Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
- 08/23/2024 - 01:25 Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
- 08/22/2024 - 07:00 Moderna to Host Investor Event - R&D Day and Business Updates
- 08/22/2024 - 00:00 Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
